Articles with public access mandates - Paolo NuciforoLearn more
OverallGovernment of SpainNIHEuropean CommissionBanking Foundation "la Caixa"Cancer Research UKSusan G. KomenNIHRAIRC Foundation for Cancer Research in ItalyMRCGovernment of ItalyDoDBreast Cancer Now, UKCIHRWorldwide Cancer Research, UKUK Research & InnovationSNSFDFGCPRITDOEUSEDHHMINHMRCFNRSFWOCCSFRQSNSERCINSERMHEASFIFCTWellcomeKWFNational Research Foundation, Singapore
Not available anywhere: 8
Analysis of the PD-1/PD-L1 axis in human autoimmune thyroid disease: Insights into pathogenesis and clues to immunotherapy associated thyroid autoimmunity
D Álvarez-Sierra, A Marín-Sánchez, P Ruiz-Blázquez, C de Jesús Gil, ...
Journal of autoimmunity 103, 102285, 2019
Mandates: Government of Spain
ESMO scale for clinical actionability of molecular targets driving targeted treatment in patients with cholangiocarcinoma
H Verdaguer, T Saurí, DA Acosta, M Guardiola, A Sierra, J Hernando, ...
Clinical Cancer Research 28 (8), 1662-1671, 2022
Mandates: Banking Foundation "la Caixa", Government of Spain
A novel EGFRvIII T-cell bispecific antibody for the treatment of glioblastoma
R Iurlaro, I Waldhauer, E Planas-Rigol, E Bonfill-Teixidor, A Arias, ...
Molecular Cancer Therapeutics 21 (10), 1499-1509, 2022
Mandates: US Department of Energy, US National Institutes of Health, German Research …
Impact of anti-HER2 therapy alone and with weekly paclitaxel on the ovarian reserve of young women with HER2-positive breast cancer
M Lambertini, M Ceppi, RA Anderson, DA Cameron, M Bruzzone, ...
Journal of the National Comprehensive Cancer Network 21 (1), 33-41. e16, 2023
Mandates: UK Medical Research Council, Government of Italy, AIRC Foundation for Cancer …
Integrated molecular and immune phenotype of HER2-positive breast cancer and response to neoadjuvant therapy: a NeoALTTO exploratory analysis
S Pizzamiglio, CM Ciniselli, T Triulzi, C Gargiuli, L De Cecco, ...
Clinical Cancer Research 27 (23), 6307-6313, 2021
Mandates: AIRC Foundation for Cancer Research in Italy
RAGE/SNAIL1 signaling drives epithelial-mesenchymal plasticity in metastatic triple-negative breast cancer
M Pujals, C Mayans, C Bellio, O Méndez, E Greco, R Fasani, ...
Oncogene 42 (35), 2610-2628, 2023
Mandates: Government of Spain
Cancer Core Europe: Leveraging Institutional Synergies to Advance Oncology Research and Care Globally
J Carmona, E Chavarria, K Donoghue, C von Gertten, P Oberrauch, ...
Cancer Discovery, OF1-OF7, 2024
Mandates: European Commission
2314P Quality and safety of research biopsies (RB) in oncology clinical trials
PG Nuciforo, F Ruiz-Pace, J Jimenez, R Comas, R Fasani, C Viaplana, ...
Annals of Oncology 34, S1182-S1183, 2023
Mandates: Banking Foundation "la Caixa"
Available somewhere: 113
Analysis of Fusobacterium persistence and antibiotic response in colorectal cancer
S Bullman, CS Pedamallu, E Sicinska, TE Clancy, X Zhang, D Cai, ...
Science 358 (6369), 1443-1448, 2017
Mandates: US National Institutes of Health, Howard Hughes Medical Institute
Assessing tumor-infiltrating lymphocytes in solid tumors: a practical review for pathologists and proposal for a standardized method from the International Immuno-Oncology …
S Hendry, R Salgado, T Gevaert, PA Russell, T John, B Thapa, M Christie, ...
Advances in anatomic pathology 24 (6), 311-335, 2017
Mandates: US National Institutes of Health, Government of Spain
Assessing tumor-infiltrating lymphocytes in solid tumors: a practical review for pathologists and proposal for a standardized method from the international immunooncology …
S Hendry, R Salgado, T Gevaert, PA Russell, T John, B Thapa, M Christie, ...
Advances in anatomic pathology 24 (5), 235-251, 2017
Mandates: US National Institutes of Health
Tumor-infiltrating lymphocytes and associations with pathological complete response and event-free survival in HER2-positive early-stage breast cancer treated with lapatinib …
R Salgado, C Denkert, C Campbell, P Savas, P Nuciforo, C Aura, ...
JAMA oncology 1 (4), 448-455, 2015
Mandates: US National Institutes of Health, National Health and Medical Research …
Capturing intra-tumor genetic heterogeneity by de novo mutation profiling of circulating cell-free tumor DNA: a proof-of-principle
L De Mattos-Arruda, B Weigelt, J Cortes, HH Won, CKY Ng, P Nuciforo, ...
Annals of oncology 25 (9), 1729-1735, 2014
Mandates: US National Institutes of Health
RAD51 foci as a functional biomarker of homologous recombination repair and PARP inhibitor resistance in germline BRCA-mutated breast cancer
C Cruz, M Castroviejo-Bermejo, S Gutiérrez-Enríquez, A Llop-Guevara, ...
Annals of Oncology 29 (5), 1203-1210, 2018
Mandates: US National Institutes of Health, Cancer Research UK, European Commission …
HER2-enriched subtype as a predictor of pathological complete response following trastuzumab and lapatinib without chemotherapy in early-stage HER2-positive breast cancer …
A Llombart-Cussac, J Cortés, L Paré, P Galván, B Bermejo, N Martínez, ...
The lancet oncology 18 (4), 545-554, 2017
Mandates: Government of Spain, Susan G. Komen
PIK3CA Mutations Are Associated With Decreased Benefit to Neoadjuvant Human Epidermal Growth Factor Receptor 2–Targeted Therapies in Breast Cancer
IJ Majewski, P Nuciforo, L Mittempergher, AJ Bosma, H Eidtmann, ...
Journal of Clinical Oncology 33 (12), 1334-1339, 2015
Mandates: US National Institutes of Health
Intrinsic subtypes and gene expression profiles in primary and metastatic breast cancer
JM Cejalvo, E Martínez de Dueñas, P Galván, S García-Recio, ...
Cancer research 77 (9), 2213-2221, 2017
Mandates: US National Institutes of Health, Government of Spain, Susan G. Komen
Recommendations for standardized pathological characterization of residual disease for neoadjuvant clinical trials of breast cancer by the BIG-NABCG collaboration
V Bossuyt, E Provenzano, WF Symmans, JC Boughey, C Coles, ...
Annals of oncology 26 (7), 1280-1291, 2015
Mandates: US National Institutes of Health, Cancer Research UK
A RAD 51 assay feasible in routine tumor samples calls PARP inhibitor response beyond BRCA mutation
M Castroviejo‐Bermejo, C Cruz, A Llop‐Guevara, S Gutiérrez‐Enríquez, ...
EMBO molecular medicine 10 (12), e9172, 2018
Mandates: US National Institutes of Health, Canadian Institutes of Health Research …
Brn-2 represses microphthalmia-associated transcription factor expression and marks a distinct subpopulation of microphthalmia-associated transcription factor–negative melanoma …
J Goodall, S Carreira, L Denat, D Kobi, I Davidson, P Nuciforo, RA Sturm, ...
Cancer research 68 (19), 7788-7794, 2008
Mandates: National Institute of Health and Medical Research, France
Publication and funding information is determined automatically by a computer program